Tech Center 1600 • Art Units: 1614 1629
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18277048 | LRAT INHIBITORS FOR TREATING SKIN AGEING | Non-Final OA | DSM IP Assets B.V. |
| 18331682 | MDMA ENANTIOMERS | Non-Final OA | Mind Medicine, Inc. |
| 17769037 | TLR7/8 AGONISTS TO ENHANCE IMMUNE RESPONSES IN OPIOID USING INDIVIDUALS | Final Rejection | Regents of the University of Minnesota |
| 17923838 | Translation Blockers Repurposed for COVID-19 Therapy | Non-Final OA | The General Hospital Corporation |
| 18858080 | CRYSTALLINE QUATERNARY SALTS OF 4-SUBSTITUTED TRYPTAMINES | Non-Final OA | CAAMTECH, INC. |
| 18297370 | DIALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES | Final Rejection | CAAMTECH, INC. |
| 18180685 | DIALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES | Final Rejection | CAAMTECH, INC. |
| 18609450 | Treating Gastric Cancer Using TTFields Combined with XELOX, FOLFOX or the Individual Constituents Thereof | Non-Final OA | Novocure GmbH |
| 18001917 | MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTAT | Non-Final OA | Mitsubishi Tanabe Pharma Corporation |
| 18341584 | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH AN IMPRINTING DEFECT | Non-Final OA | The Children's Medical Center Corporation |
| 18008947 | Administration of Resiniferatoxin For Treatment of Bladder Pain or Bladder Cancer | Non-Final OA | Sorrento Therapeutics, Inc. |
| 18556616 | MOLEPHANTIN DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Non-Final OA | Nanyang Herbs Pte. Ltd. |
| 18380245 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | Non-Final OA | Sistema Universitario Ana G. Mendez, Inc. |
| 18273407 | FIXED DOSAGE ANTIBIOTIC COMPOSITIONS | Final Rejection | Entasis Therapeutics Limited |
| 18269825 | PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC KIDNEY DISEASE | Non-Final OA | CURED Inc. |
| 18214137 | COMPOSITION OF ACTIVE AGENTS TO POSITIVELY AFFECT A ROBUST MAMMALIAN ENDOCANNABINOID SYSTEM TONE TO BETTER ADDRESS AGE RELATED DISCOMFORT | Non-Final OA | Compact Disc Incorporated |
| 18246522 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | Non-Final OA | TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY |
| 16955699 | USE FOR PROTECTING OR MITIGATING RADIATION DAMAGE, AND FOR PREVENTING OR TREATING PULMONARY FIBROSIS | Non-Final OA | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES |
| 17911965 | MITOCHONDRIAL DYSFUNCTION IMPROVING AGENT | Final Rejection | Penta Labor Inc. |
| 17909650 | ANTIVIRAL TREATMENT | Non-Final OA | TRANSMARE CHEMIE NV |
| 17904031 | ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES | Final Rejection | Klinikum Rechts Der Isar der Technischen Universitaet Muenchen |
| 17793037 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | Non-Final OA | ConSynance Therapeutics, Inc. |
| 17790905 | COMPOSITIONS AND METHODS FOR INCREASING CELLULAR VITALITY AND LONGEVITY AND DECREASING MOLECULAR AGEING | Final Rejection | JUVN3 Holdings, LLC |
| 17722236 | COMPOSITIONS AND METHODS OF TREATING ACNE AND PHOTOAGING | Final Rejection | Curology, Inc. |
| 17372753 | ENHANCED PURITY AND METHODS OF USE OF ABLATIVE ALCOHOL | Non-Final OA | Belcher Pharmaceuticals, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy